Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06345963 · ClinicalTrials.gov registry record · NA
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
A NA study of Schizophrenia, sponsored by The University of Texas Health Science Center, Houston.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT06345963: Recruiting NA study of Schizophrenia, sponsored by The University of Texas Health Science Center, Houston.
NCT06345963 is a NA study of Schizophrenia that is actively recruiting participants, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 120 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06345963, a NA study of Schizophrenia, is actively recruiting participants, sponsored by The University of Texas Health Science Center, Houston.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from H coil for improving white matter integrity.
Primary Outcome
Fractional anisotropy (FA) values will be reported. FA values range from 0 to 1 with larger values indicating greater white matter integrity.
Conditions Studied
Interventions
- DEVICE active H-coil delivered rTMS
Study Locations (1)
Texas
- The University of Texas Health Science Center, Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-05-21 |
| Est. Completion | 2030-05-01 |
| Phase | NA |
What NCT06345963 shows while recruiting
NCT06345963 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (45% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which active H-coil delivered rTMS is the first listed.
NCT06345963 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06345963 about?
NCT06345963 is a clinical study titled "Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)". Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from H coil for improving white matter integrity.
What is the current status of trial NCT06345963?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2024-05-21. Estimated completion is 2030-05-01.
What conditions does trial NCT06345963 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT06345963?
The interventions under investigation include: active H-coil delivered rTMS (DEVICE).
Who is sponsoring clinical trial NCT06345963?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06345963 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06345963's enrollment target sits among peer trials
120 120th of 315 higher than 190 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
TMS for Inhibition Enhancement in Schizophrenia
RECRUITING · NA
-
Decision-Making in Schizophrenia: A Combined Neuroimaging and Experience Sampling Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI